Ovarian Cancer Breakthrough: Repurposed Drug Shows Promise in Aggressive Platinum-Resistant Cases
** A groundbreaking clinical trial has shown that a repurposed drug, Relacorilant, can potentially extend the survival of patients with aggressive platinum-resistant ovarian cancer. Administered to 57 patients, the study’s findings suggest a promising direction for future research.
Read More